Dr. Katharina Severin
Investment Manager
About me
| Team | Life Sciences & Chemistry |
| at HTGF since | 2021 |
CV
Katharina Severin joined the Life Science Team in September of 2021. She was born and raised in the Ruhr area and spent time in the US and Asia during her education. Among these stays was a one-year research stay in the lab of Tom Rapoport at Harvard Medical School in Boston. Katharina obtained her PhD in Medical Biology and received numerous scholarships and awards, among them stipends from the German National Academic Foundation and the Christiane Nüsslein-Volhard Foundation. Through networking opportunities from these foundations and as an attendee of the Lindau Nobel Laureate Meeting, Katharina discovered and cultivated her passion for interdisciplinary scientific exchange. Her research findings mark a starting point for a novel therapeutic approach in the treatment of cancer. Katharina is fascinated by entrepreneurial questions and is passionate about bringing scientific results and genious business ideas to profitable ventures.
My success stories in the HTGF portfolio
Akribion Therapeutics is developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion. Our G-dase® E nuclease has the ability to kill cells by shredding DNA and RNA, but only …
Heidelberg Epignostix is a healthcare company whose mission is to transform cancer diagnostics through data science. The company has developed novel AI-based bioinformatics algorithms with utility in cancer classification for …
Phialogics is an innovative start-up in the field of autoimmune diseases. Founded in 2021 by a team of widely recognized experts in protein engineering and immunology, the company based in …
Smarterials Technology GmbH is a young MedTech company with high competence in the fields of inorganic chemistry, surface functionalization and process technology. The company was founded by two material scientists …
Cutanos GmbH is a biotech company founded in early 2021 focussing on the development of antigen-specific vaccines and new treatments for autoimmune disorders. Cutanos uses a modular and highly flexible …
FundaMental Pharma GmbH (FMP) is developing new types of drugs that act as ‘molecular spacers’ and disrupt a death signaling complex in the brain. Using this pharmacological strategy, FMP scientists …
Guided to exit
Recent posts
Zum Artikel
Akribion Therapeutics exits from stealth with €8m seed financing to pioneer RNA-guided, programmable cell depletion
Zum Artikel
DKFZ spin-off Epignostix raises €4.3m Seed round to commercialize diagnostic tumor classifier
Zum Artikel
Social Media & contact
LinkedIn
Dr. Katharina Severin
Profil